Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Depressive Disorder 1 Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

NCT01413932
View directory record Official record
Conditions
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions
HT-2157, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)

NCT01110902
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Costa Mesa, California • El Centro, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Jul 21, 2026, 11:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

NCT06671977
View directory record Official record
Conditions
Major Depression Disorder, Depression
Interventions
DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose, THC-Low Dose
Drug
Lead sponsor
Deepak C. D'Souza
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

NCT00250601
View directory record Official record
Conditions
Depressive Disorder
Interventions
Saredutant succinate (SR48968C)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 64 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

NCT01670279
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
70 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Kissimmee, Florida • Miami, Florida • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

NCT02722967
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions
Aripiprazole + IEM (Ingestible Event Marker)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Not applicable Interventional Results available

Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder

NCT03288714
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode, Major Depressive Disorder
Interventions
Synchronized Transcranial Magnetic Stimulation (sTMS), Sham Stimulation
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
22 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jul 21, 2026, 11:24 PM EDT
Terminated No phase listed Observational

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

NCT04353921
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
No intervention will be administered as part of this study.
Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lauderhill, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 21, 2026, 11:24 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

NCT05227209
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

NCT00644358
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
38
States / cities
Garden Grove, California • San Diego, California • Torrance, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jul 21, 2026, 11:24 PM EDT
Recruiting Phase 3 Interventional

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
View directory record Official record
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Chino, California • Redlands, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

NCT01110889
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Agomelatine (AGO178C), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

NCT06360419
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Solriamfetol 300 mg, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Little Rock, Arkansas • Bellflower, California • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

NCT03155503
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SUVN-911, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Jul 21, 2026, 11:24 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

NCT01944657
View directory record Official record
Conditions
1. Major Depressive Disorder
Interventions
Supplemental TMS, Standard Medication Monotherapy
Device · Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine

NCT00825019
View directory record Official record
Conditions
Major Depressive Disorders
Interventions
amibegron (SR58611A), placebo, paroxetine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Jul 21, 2026, 11:24 PM EDT
Completed No phase listed Observational

Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

NCT02474680
View directory record Official record
Conditions
Major Depressive Disorder 1
Interventions
Pharmacogenetic testing
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Not applicable Interventional

NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient

NCT06772987
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Accelerated rTMS treatment
Device
Lead sponsor
NeuroQore Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

NCT03864614
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAGE-217
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
52
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Jul 21, 2026, 11:24 PM EDT
Terminated Phase 4 Interventional Results available

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

NCT03643159
View directory record Official record
Conditions
Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
Interventions
Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
Combination Product · Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Santa Rosa, California • Decatur, Georgia • Smyrna, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

NCT03543410
View directory record Official record
Conditions
Depressive Episode, Bipolar 1 Depression
Interventions
SEP-4199 200 mg, SEP-4199 400 mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Cerritos, California • Garden Grove, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Jul 21, 2026, 11:24 PM EDT
Completed Not applicable Interventional

Effects of Respiratory-Gated Transcutaneous Vagal Nerve Stimulation in Major Depression (Phase 1)

NCT04607226
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active transcutaneous vagus nerve stimulation, Sham transcutaneous vagus nerve stimulation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
24 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 21, 2026, 11:24 PM EDT
Recruiting No phase listed Observational

ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

NCT07528014
View directory record Official record
Conditions
Depressed Mood
Interventions
Not listed
Lead sponsor
Salma Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
2
States / cities
La Jolla, California • Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 21, 2026, 11:24 PM EDT